IP Library Granted Patent US 9,895,342
Granted Patent B2
US 9,895,342 · App. 14/118,563 · Granted Feb 20, 2018

Cannabinoids for use in the treatment of neuropathic pain

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,895,342
App. No.
14/118,563
Granted
Feb 20, 2018
Kind
B2
Abstract

The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.

Claims (9)

1. A method of treating a patient with neuropathic pain consisting essentially of administering to the patient an effective amount of cannabidivarin (CBDV) wherein the CBDV is of a purity of greater than 99% (w/w), or is produced synthetically and does not include cannabidiol (CBD) and/or tetrahydrocannabinol (THC).

2. The method as claimed in claim 1 , wherein the neuropathic pain is peripheral neuropathic pain.

3. The method as claimed in claim 2 , wherein the peripheral neuropathic pain is allodynia.

4. The method as claimed in claim 1 , wherein the CBDV is present in an effective human daily dose to relieve neuropathic pain.

5. The method as claimed in claim 4 , wherein the effective human daily dose of CBDV is between 5 mg and 100 mg.

6. The method as claimed in claim 5 , wherein the effective human daily dose of CBDV is between 10 mg and 50 mg.

7. The method as claimed in claim 1 , wherein the CBDV is packaged for use for an extended treatment period.

8. The method as claimed in claim 7 , wherein the extended treatment period is at least 7 days.

9. The method as claimed in claim 1 , wherein the CBDV is administered to the patient in combination with one or more other medicinal substances used in the treatment of neuropathic pain.

Assignments (4)
CHANGE OF NAME Recorded May 13, 2025
From: GW PHARMA LIMITED
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED
Reel/Frame 071097/0088 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2017
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 043959/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2014
From: MAIONE, SABATINO; ROSSI, FRANCESCO; GUY, GEOFFREY; STOTT, COLIN; KIKUCHI, TETSURO
To: GW PHARMA LIMITED; OTSUKA PHARMACEUTICAL CO. LIMITED
Reel/Frame 032132/0602 →